戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rgets, as evidenced by the recent success of erenumab.
2  consistent with the known safety profile of erenumab.
3 s after receiving her second monthly dose of erenumab.
4 246 (97.6%) entered the OLEP (118 continuing erenumab, 122 switching from placebo).
5  was not significantly different between the erenumab (13 [31.7%]) and placebo (18 [45.0%]) groups (o
6  placebo (n=286), erenumab 70 mg (n=191), or erenumab 140 mg (n=190).
7  open-label extension phase (OLEP) receiving erenumab 140 mg monthly for up to 3 years.
8 ventives were randomised 1:1 to subcutaneous erenumab 140 mg or placebo every 4 weeks for 12 weeks.
9  to subcutaneous placebo, erenumab 70 mg, or erenumab 140 mg, given every 4 weeks for 12 weeks.
10 1 randomization, followed by another dose of erenumab (140 mg subcutaneously) or placebo 4 weeks late
11          At month 6, 134 participants in the erenumab, 140 mg group (69.1%) (odds ratio [OR], 2.01; 9
12 rage monthly AHMD was -9.4 (0.4) days in the erenumab, 140 mg group (difference from placebo, -2.7; 9
13  (49.5%), and 73 participants (37.6%) in the erenumab, 140 mg, 70 mg, and placebo groups, respectivel
14 (95% CI, -1.6 to -0.2) in those who received erenumab, 140 mg, compared with placebo.
15 (95% CI, -4.8 to -1.4) in those who received erenumab, 140 mg.
16                              Loading dose of erenumab (280 mg subcutaneously) or matching placebo in
17 andomly assigned to receive placebo (n=286), erenumab 70 mg (n=191), or erenumab 140 mg (n=190).
18                                              Erenumab 70 mg and 140 mg reduced monthly migraine days
19 RETATION: In patients with chronic migraine, erenumab 70 mg and 140 mg reduced the number of monthly
20 ly assigned (3:2:2) to subcutaneous placebo, erenumab 70 mg, or erenumab 140 mg, given every 4 weeks
21                          One or more dose of erenumab (70 mg or 140 mg once per month) or placebo was
22 33-3.05; P < .001 vs placebo) and 117 in the erenumab, 70 mg group (60.3%) (OR, 1.37; 95% CI, 0.92-2.
23 o -1.6; P < .001) and -7.8 (0.4) days in the erenumab, 70 mg group (difference from placebo, -1.2; 95
24 als, 1400 (52.2%) received 1 or more dose of erenumab, 70 mg or 140 mg, and 1043 (38.9%) received pla
25 -label or dose-blinded active treatment, and erenumab, 70 mg or 140 mg, was administered once per mon
26                                              Erenumab, 70 mg, 140 mg, or placebo, once monthly for 24
27 (95% CI, -1.7 to -0.6) in those who received erenumab, 70 mg, and -0.9 (95% CI, -1.6 to -0.2) in thos
28 (95% CI, -3.8 to -0.5) in those who received erenumab, 70 mg, and -3.1 (95% CI, -4.8 to -1.4) in thos
29                     The potential effects of erenumab, a CGRP receptor antagonist monoclonal antibody
30       We assessed the efficacy and safety of erenumab, a fully human monoclonal antibody against the
31                                    We tested erenumab, a fully human monoclonal antibody that inhibit
32                                              Erenumab administered subcutaneously at a monthly dose o
33 eekly CH attacks was -7.3 (8.6) per week for erenumab and -5.9 (10.5) per week for placebo (group dif
34                                  Contrasting erenumab and galcanezumab showed that both antibodies ac
35 rates of adverse events were similar between erenumab and placebo.
36  understand long-term efficacy and safety of erenumab, and the applicability of this study to real-wo
37 cal laboratory values, vital signs, and anti-erenumab antibodies.
38          Substantially fewer patients in the erenumab arm compared with the OMPM arm switched medicat
39 o receive a subcutaneous injection of either erenumab, at a dose of 70 mg or 140 mg, or placebo month
40 group and three in the 140 mg group had anti-erenumab binding antibodies; none had anti-erenumab neut
41  similar to placebo, providing evidence that erenumab could be a potential therapy for migraine preve
42 nd, placebo-controlled, multicentre study of erenumab for adults aged 18-65 years with chronic migrai
43  achieved for 43.3% of patients in the 70-mg erenumab group and 50.0% of patients in the 140-mg erenu
44 ication was reduced by 1.1 days in the 70-mg erenumab group and by 1.6 days in the 140-mg erenumab gr
45 mber of days was reduced by 3.2 in the 70-mg erenumab group and by 3.7 in the 140-mg erenumab group,
46 ent adverse events incidence in the combined erenumab group was 66.8% (259 participants; constipation
47 andomization: 317 were assigned to the 70-mg erenumab group, 319 to the 140-mg erenumab group, and 31
48  the 70-mg erenumab group, 319 to the 140-mg erenumab group, and 319 to the placebo group.
49 erenumab group and by 1.6 days in the 140-mg erenumab group, as compared with 0.2 days in the placebo
50 0-mg erenumab group and by 3.7 in the 140-mg erenumab group, as compared with 1.8 days in the placebo
51 ab group and 50.0% of patients in the 140-mg erenumab group, as compared with 26.6% in the placebo gr
52 ears; 545 female [87.8%]; 413 [66.5%] in the erenumab group; 208 [33.5%] in the OMPM group), 523 (84.
53             AHMD use was also reduced in the erenumab groups vs placebo.
54 y 4.2 and 4.8 points in the 70-mg and 140-mg erenumab groups, respectively, as compared with 2.4 poin
55 y 5.5 and 5.9 points in the 70-mg and 140-mg erenumab groups, respectively, as compared with 3.3 poin
56 nical trial demonstrated that earlier use of erenumab in patients with EM who failed 1 or 2 previous
57 ngs support the efficacy and safety of using erenumab in this patient population.
58 tions included galcanezumab (in 3 patients), erenumab (in 5 patients), and fremanezumab (in 1 patient
59              In this study, monthly, 140 mg, erenumab injections safely and effectively achieved MOH
60                                              Erenumab is a monoclonal antibody targeting the calciton
61  (mean [SD], 21.5 [9.7] attacks per week) to erenumab (n = 41) or placebo (n = 40).
62 i-erenumab binding antibodies; none had anti-erenumab neutralising antibodies.
63    Patients were randomized (2:1) to receive erenumab or OMPMs.
64 graine and were randomized to receive either erenumab or placebo.
65  sustained benefit of 2 treatment paradigms (erenumab qm vs oral prophylactics) in adult episodic mig
66 nificantly higher proportions of patients on erenumab reported a 5-point reduction (OR (95% CI): 2.4
67 -term safety and durability of the effect of erenumab require further study.
68          Compared with OMPMs, treatment with erenumab showed higher responder rate (314 of 413 [76.0%
69           In three out of four WPAI domains, erenumab showed improvement versus placebo.
70                                              Erenumab significantly improved MPFID-Physical Impairmen
71 re participants reported adverse events with erenumab than placebo (27 [65.9%] vs 17 [42.5%]), which
72 eline MMDs and AMSM days were greater in the erenumab than placebo groups in patients with and withou
73 educed migraine frequency and AMSM days with erenumab treatment in patients with migraine with and wi
74 in cumulative average MMDs was reported with erenumab treatment vs OMPM treatment (-4.32 vs -2.65; tr
75                                              Erenumab treatment was safe and well tolerated, in-line
76  12, significantly more patients assigned to erenumab vs OMPM achieved the primary end point (232 of
77                                              Erenumab was discontinued, but at her following visit fo
78                                 At 12 weeks, erenumab was efficacious on functional outcomes in patie
79 with CCH, blockade of the CGRP receptor with erenumab was not successful in the prophylaxis of attack
80 dy which investigated the CGRP receptor mAb (erenumab), we hypothesized that (i) the CGRP ligand mAb
81                                  Patients on erenumab were more likely to have a 5-point reduction in
82 y exacerbated by CGRP receptor blockade from erenumab, which may have impaired compensatory vasodilat